Literature DB >> 28105765

Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.

Marco Guazzi1, Loek van Heerebeek2, Walter J Paulus2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28105765     DOI: 10.1002/ejhf.742

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  3 in total

1.  Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.

Authors:  Renato De Vecchis; Arturo Cesaro; Carmelina Ariano; Anna Giasi; Carmela Cioppa
Journal:  J Clin Med Res       Date:  2017-04-26

Review 2.  Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System.

Authors:  Maria Ercu; Enno Klussmann
Journal:  J Cardiovasc Dev Dis       Date:  2018-02-20

3.  Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.

Authors:  Renato De Vecchis; Arturo Cesaro; Carmelina Ariano
Journal:  Interv Med Appl Sci       Date:  2017-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.